Mycophenolate mofetil in pediatric renal transplantation: A single center experience.

Hdl Handle:
http://hdl.handle.net/10147/132335
Title:
Mycophenolate mofetil in pediatric renal transplantation: A single center experience.
Authors:
Raheem, Omer A; Kamel, Mohamed H; Daly, Padraiq J; Mohan, Ponnusamy; Little, Dilly M; Awan, Atif; Hickey, David P
Affiliation:
Departments of Urology and Transplantation, Beaumont Hospital, Beaumont, Ireland Temple Street Hospital for Sick Children, Dublin, Ireland.
Citation:
Mycophenolate mofetil in pediatric renal transplantation: A single center experience. 2011, 15 (3):240-4 Pediatr Transplant
Journal:
Pediatric transplantation
Issue Date:
May-2011
URI:
http://hdl.handle.net/10147/132335
DOI:
10.1111/j.1399-3046.2009.01179.x
PubMed ID:
21492350
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21492350
Abstract:
Raheem OA, Kamel MH, Daly PJ, Mohan P, Little DM, Awan A, Hickey DP. Mycophenolate mofetil in pediatric renal transplantation: A single center experience. Pediatr Transplantation 2011: 15:240-244. © 2009 John Wiley & Sons A/S. Abstract:  We assessed our long-term experience with regards to the safety and efficacy of MMF in our pediatric renal transplant population and compared it retrospectively to our previous non-MMF immunosuppressive regimen. Forty-seven pediatric renal transplants received MMF as part of their immunosuppressive protocol in the period from January 1997 till October 2006 (MMF group). A previously reported non-MMF group of 59 pediatric renal transplants was included for comparative analysis (non-MMF group). The MMF group comprised 29 boys and 18 girls, whereas the non-MMF group comprised 34 boys and 25 girls. Mean age was 11.7 and 12 yr in the MMF and non-MMF groups, respectively. The incidence of acute rejection episodes was 11 (23.4%) and 14 (24%) in the MMF and non-MMF group, respectively. Two (3.3%) grafts were lost in the non-MMF group compared with one (2.1%) in the MMF group. Twenty-one (44.68%) patients in the MMF group developed post-transplant infections compared with 12 (20.33%) in the non-MMF group (p < 0.0001). In conclusion, the use of MMF in pediatric renal transplantation was not associated with a lower rejection rate or immunological graft loss. It did, however, result in a significantly higher rate of viral infections.
Item Type:
Article
Language:
en
ISSN:
1399-3046

Full metadata record

DC FieldValue Language
dc.contributor.authorRaheem, Omer Aen
dc.contributor.authorKamel, Mohamed Hen
dc.contributor.authorDaly, Padraiq Jen
dc.contributor.authorMohan, Ponnusamyen
dc.contributor.authorLittle, Dilly Men
dc.contributor.authorAwan, Atifen
dc.contributor.authorHickey, David Pen
dc.date.accessioned2011-05-30T15:26:08Z-
dc.date.available2011-05-30T15:26:08Z-
dc.date.issued2011-05-
dc.identifier.citationMycophenolate mofetil in pediatric renal transplantation: A single center experience. 2011, 15 (3):240-4 Pediatr Transplanten
dc.identifier.issn1399-3046-
dc.identifier.pmid21492350-
dc.identifier.doi10.1111/j.1399-3046.2009.01179.x-
dc.identifier.urihttp://hdl.handle.net/10147/132335-
dc.description.abstractRaheem OA, Kamel MH, Daly PJ, Mohan P, Little DM, Awan A, Hickey DP. Mycophenolate mofetil in pediatric renal transplantation: A single center experience. Pediatr Transplantation 2011: 15:240-244. © 2009 John Wiley & Sons A/S. Abstract:  We assessed our long-term experience with regards to the safety and efficacy of MMF in our pediatric renal transplant population and compared it retrospectively to our previous non-MMF immunosuppressive regimen. Forty-seven pediatric renal transplants received MMF as part of their immunosuppressive protocol in the period from January 1997 till October 2006 (MMF group). A previously reported non-MMF group of 59 pediatric renal transplants was included for comparative analysis (non-MMF group). The MMF group comprised 29 boys and 18 girls, whereas the non-MMF group comprised 34 boys and 25 girls. Mean age was 11.7 and 12 yr in the MMF and non-MMF groups, respectively. The incidence of acute rejection episodes was 11 (23.4%) and 14 (24%) in the MMF and non-MMF group, respectively. Two (3.3%) grafts were lost in the non-MMF group compared with one (2.1%) in the MMF group. Twenty-one (44.68%) patients in the MMF group developed post-transplant infections compared with 12 (20.33%) in the non-MMF group (p < 0.0001). In conclusion, the use of MMF in pediatric renal transplantation was not associated with a lower rejection rate or immunological graft loss. It did, however, result in a significantly higher rate of viral infections.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21492350en
dc.titleMycophenolate mofetil in pediatric renal transplantation: A single center experience.en
dc.typeArticleen
dc.contributor.departmentDepartments of Urology and Transplantation, Beaumont Hospital, Beaumont, Ireland Temple Street Hospital for Sick Children, Dublin, Ireland.en
dc.identifier.journalPediatric transplantationen
dc.description.provinceLeinster-

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.